GED 0507-34-Levo

Drug Profile

GED 0507-34-Levo

Alternative Names: GED-0507; GED-0507-34; N-acety-GED-0507-34

Latest Information Update: 05 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Giuliani
  • Developer Nogra Pharma
  • Class Anti-inflammatories; Antiulcers
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris
  • No development reported Ulcerative colitis

Most Recent Events

  • 02 Jul 2016 Phase-II clinical trials in Acne vulgaris in Hungary (Topical) (EudraCT2016-000540-33)
  • 20 Jun 2016 PPM Services plans the proof-of-concept phase II SEGMENT trial for Ulcerative colitis in Canada and USA (PO) (NCT02808390)
  • 13 Sep 2015 No recent reports of development identified - Phase-II for Ulcerative colitis in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top